The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Ginkgo Bioworks (DNA). While the effectiveness of this highly sought-after metric is questionable, the ...

Ginkgo Bioworks gains a $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems.

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...

Part of the partners' plan is to use Plex's AI to identify potential new uses for existing treatments that can be used to ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Humacyte (HUMA) 20.80% +5.81, Ginkgo Bioworks ...